Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients
- Conditions
- Pneumocystis Jirovecii Infection
- Registration Number
- NCT05458752
- Lead Sponsor
- Central Hospital, Nancy, France
- Brief Summary
Pneumocystis jirovecii pneumonia (PjP) is a rare infectiouse disease with a high level of mortality. PjP is a classical opportunistic infection which concern HIV infected and immunocompromised patients. During the past decade, several therapeutic's progresses have been done in oncology, immunology and hematology. As a consequence, patients benefited of greater treatment efficacy but are exposed to a higher risk of opportunistic infections as PjP. The investigators hypothesis is that PjP incidence increase and its form is depending of underlying immune conditions. The investigators aim to describe its incidence, the PjP forms depending on comorbidities and to identifiy pronostics factors.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 133
- Underlying immune condition at risk of Pneumocystis jirovecii pneumonia excluding HIV infection
- Clinical, biological and radiological presentation which evoke Pneumocystis jirovecii pneumonia
- Microbiological confirmation by respiratory specimen analyses ( specific coloration and/or IFI and/or PRC)
- No microbiological confirmation by respiratory specimen analyses
- Proved HIV infection
- Patient denied to particpate
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of Pneumocystis jirovecii pneumonia in HIV-free patients Between the first january 2004 and the 31th december 2021 Number of cases / number of patients treated for a predisposing disease (heamotological or imunological disease, or cancer...)
- Secondary Outcome Measures
Name Time Method To describe clinical features of Pneumocystis jirovecci pneumonia in HIV-free patients Between the first january 2004 and the 31th december 2021 Type of first symptoms as categorial variables
To describe the immunoglobulin level of HIV free patients with Pneumocystis jirovecci pneumonia Between the first january 2004 and the 31th december 2021 immunoglobulin (g/L)
To describe the albumin level of HIV free patients with Pneumocystis jirovecci pneumonia Between the first january 2004 and the 31th december 2021 albumin (g/L)
To describe the age of giv free patients with Pneumocystis jirovecci pneumonia Between the first january 2004 and the 31th december 2021 age in years
To describe the WBC level of HIV free patients with Pneumocystis jirovecci pneumonia Between the first january 2004 and the 31th december 2021 WBC (G/L)
To describe the immunofluorescence value of HIV free patients with Pneumocystis jirovecci pneumonia Between the first january 2004 and the 31th december 2021 Immunofluorescence as a categorial variable
To describe the use of pentamidine for HIV free patients with Pneumocystis carinii pneumonia Between the first january 2004 and the 31th december 2021 pentamidine as a categorial variable
To describe the body mass index of HIV free patients with Pneumocystis jirovecci pneumonia Between the first january 2004 and the 31th december 2021 BMI in kg/m2 (quanti
To describe the Charlson comorbidity index of HIV free patients with Pneumocystis jirovecci pneumonia Between the first january 2004 and the 31th december 2021 Charlson comorbidity index as a quantitative variable
To describe the date of the first symptoms of Pneumocystis jirovecci pneumonia in HIV-free patients Between the first january 2004 and the 31th december 2021 Date of first symptoms as quantitative variable
To describe the comoribidites of HIV-free patients with Pneumocystis jirovecci pneumonia Between the first january 2004 and the 31th december 2021 Comorbidities as categorial variables
To describe the PCR level of HIV free patients with Pneumocystis jirovecci pneumonia Between the first january 2004 and the 31th december 2021 PCR (mg/L)
To describe the previous medications used by HIV free patients with Pneumocystis jirovecci pneumonia Between the first january 2004 and the 31th december 2021 Medications as categorial variables
To describe the pO2 level of HIV free patients with Pneumocystis jirovecci pneumonia Between the first january 2004 and the 31th december 2021 pO2 (in mmHg)
To describe the creatinine level of HIV free patients with Pneumocystis jirovecci pneumonia Between the first january 2004 and the 31th december 2021 Creatinine (µmol/L)
To describe the LDH level of HIV free patients with Pneumocystis jirovecci pneumonia Between the first january 2004 and the 31th december 2021 LDH (MUI/L)
To describe the lymphocytes level of HIV free patients with Pneumocystis jirovecci pneumonia Between the first january 2004 and the 31th december 2021 lymphocytes (G/L)
To describe the PCR pneumocystis level of HIV free patients with Pneumocystis jirovecci pneumonia Between the first january 2004 and the 31th december 2021 PCR pneumocystis in ct
To describe the specific coloration value of HIV free patients with Pneumocystis jirovecci pneumonia Between the first january 2004 and the 31th december 2021 Specific coloration as a categorial variable
To describe the use of nasal canula in HIV free patient with a Pneumocystis jirovecci pneumonia Between the first january 2004 and the 31th december 2021 Nasal canula as a categorial variable
To describe the use of high flow oxygenation in HIV free patient with a Pneumocystis jirovecci pneumonia Between the first january 2004 and the 31th december 2021 High flow oxygenation as a categorial variable
To describe the use of mechanical ventilation in HIV free patient with a Pneumocystis jirovecci pneumonia Between the first january 2004 and the 31th december 2021 Mechanical ventilation as a categorial variable
To describe the duration of hospitalisation of HIV free patients with Pneumocystis carinii pneumonia Between the first january 2004 and the 31th december 2021 Duration in days
To describe the use of cotrimoxazole for HIV free patients with Pneumocystis carinii pneumonia Between the first january 2004 and the 31th december 2021 cotrimoxazole as a categorial variable
To describe the use of atovaquone for HIV free patients with Pneumocystis carinii pneumonia Between the first january 2004 and the 31th december 2021 atovaquone as a categorial variable
To describe the use of steroïd for HIV free patients with Pneumocystis carinii pneumonia Between the first january 2004 and the 31th december 2021 steroïd as a categorial variable
Trial Locations
- Locations (1)
Université de Lorraine, CHRU Nancy and APEMAC
🇫🇷Vandoeuvre Les Nancy, Lorraine, France